 Shares of AbbVie Inc. ABBV, -0.55 were up 0.8 in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and commercialize Regenxbio Inc.s RGNX, -1.66 experimental gene therapy, which is being tested as a treatment for several eye diseases. Regenxbios stock jumped 18.2 on the news. 